"In responding to the speedo today, PTX missed the opportunity to educate the market about the AMGEN trial and the low hurdle needed to get FDA approval for these types of agents."
Whilst that would have been nice, maybe the asx could then argue that the company was aware of some information that could be price sensitive.
A CEO once told me that it's better to say "I know nothing" or else you could be incriminating yourself.
"In responding to the speedo today, PTX missed the opportunity...
-
- There are more pages in this discussion • 737 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
